Evidence map›Paper›PMID 31048088›Full record

ArticleContemporary clinical trials2019

Vitamin D supplementation for prevention of cancer: The D2d cancer outcomes (D2dCA) study.

Ranee Chatterjee, John K Erban, Paul Fuss, Rowena Dolor, Erin LeBlanc, Myrlene Staten, Patricia Sheehan, Anastassios Pittas, D2d Research Group

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Vitamin D deficiency 2.0: an update on the current status worldwide.European journal of clinical nutrition · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ranee ChatterjeeDivision of General Internal Medicine, 200 Morris Street, 3(rd) Floor, Box 104427, Durham, NC 27701, USA. Electronic address: ranee.chatterjee@duke.edu.
John K ErbanCancer Center, Tufts Medical Center, 800 Washington St, Box 245, Boston, MA 02111, USA. Electronic address: JErban@tuftsmedicalcenter.org.
Paul FussDivision of Endocrinology, Tufts Medical Center, 800 Washington Street, Box 268, Boston, MA 02111, USA. Electronic address: pfuss@tuftsmedicalcenter.org.
Rowena DolorDivision of General Internal Medicine, 200 Morris Street, 3(rd) Floor, Box 104427, Durham, NC 27701, USA. Electronic address: rowena.dolor@duke.edu.
Erin LeBlancKaiser Permanente Center for Health Research NW, 3800 N Interstate, Portland, OR 97229, USA. Electronic address: Erin.s.leblanc@kpchr.org.
Myrlene StatenKelly Government Services for the National Institute of Diabetes and Digestive and Kidney Diseases, 6701 Democracy Boulevard, Room 6107, Bethesda, MD 20817, USA. Electronic address: statenm@niddk.nih.gov.
Patricia SheehanSpaulding Rehabilitation Network, 300 1(st) Ave, Charlestown, MA 02129, USA. Electronic address: prsheehan@partners.org.
Anastassios PittasDivision of Endocrinology, Tufts Medical Center, 800 Washington Street, Box 268, Boston, MA 02111, USA. Electronic address: apittas@tuftsmedicalcenter.org.
D2d Research Group

Funding

Vitamin D and Type 2 Diabetes (D2d)U01DK098245 · NIDDK · TUFTS MEDICAL CENTER · PI PITTAS, ANASTASSIOS G · 2013 to 2020
$45.6M
Vitamin D for Type 2 Diabetes (D2D trial)U34DK091958 · NIDDK · TUFTS MEDICAL CENTER · PI PITTAS, ANASTASSIOS G · 2011 to 2012
$792k
NIDDK NIH HHS U01 DK098245NIDDK NIH HHS U34 DK091958
6 · The paper itself

Abstract

Evidence on biological plausibility from mechanistic studies and data from observational studies suggest that vitamin D may be linked to risk of several types of cancer. However, evidence from clinical trials evaluating the effect of vitamin D supplementation on cancer risk is limited. The Vitamin D and Type 2 Diabetes (D2d) study is a multi-center, randomized, placebo-controlled clinical trial conducted to examine the causal relationship between oral vitamin D supplementation and development of diabetes among overweight adults with prediabetes. The D2d study provides a unique opportunity to assess the effect of vitamin D supplementation at a higher dose (4000 IU/day) than has been used in other clinical trials with cancer outcomes, in a population at higher than average risk for cancer. This paper provides: Krishnan and Feldman (2011) a) baseline characteristics of the D2d population included in the D2d cancer outcomes secondary study (D2dCA) and comparison to other large trials of vitamin D supplementation and cancer risk; Leyssens et al. (2013) b) description of data that are being collected during the trial and the planned statistical analyses to test whether vitamin D supplementation at a dose of 4000 IU/day has an effect on incident cancer overall, on incidence of certain types of cancer, and on incidence of precancerous lesions. Results of D2dCA will help guide future research and clinical recommendations related to vitamin D and cancer risk.

Indexed as

CholecalciferolDiabetes Mellitus, Type 2Dietary SupplementsNeoplasmsOverweightPrediabetic StateAgedAge FactorsDouble-Blind MethodFemaleHealth BehaviorHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicCholecalciferolCancer riskD2d studyPrediabetesVitamin D

Identifiers

PMID31048088
PMCPMC6570503

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.